Another 2,300 AstraZeneca jobs go but 'simplification will lead to growth', says Soriot

 
• By Sukaina Virji
  
Generate a summary of this article
Listen to this article
Beta

AstraZeneca has outlined its strategic plans under new CEO Pascal Soriot ahead of an investor briefing in New York later today (March 21). AstraZeneca's newly stated strategic priorities include restructuring its SG&A activities with resultant significant job losses, driving its on-market growth platforms in a bid to return to growth, and achieving "scientific leadership". On the latter front, the firm announced a $240 million upfront discovery alliance with small biotech company Moderna Therapeutics, which is focused on mRNAi.

AstraZeneca has outlined its strategic plans under new CEO Pascal Soriot ahead of an investor briefing in New York later today (March 21). AstraZeneca's newly stated strategic priorities include restructuring its SG&A activities with resultant significant job losses, driving its on-market growth platforms in a bid to return to growth, and achieving "scientific leadership". On the latter front, the firm announced a $240 million upfront discovery alliance with small biotech company Moderna Therapeutics, which is focused on mRNAi.

AstraZeneca is committed to "dramatically simplifying" its organization and processes, said Mr Soriot. "Co-location on a more focused footprint will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By Xu Hu

Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.